Medical Devices

A novel gene therapy using precision-guided vectors could offer a one-time treatment for wet AMD, a leading cause of blindness, freeing patients from injections.

With a fresh CAD $1M in funding, Grey Matters is set to enter the booming U.S. neuroimaging market, targeting early Alzheimer's detection.

The Pacific Northwest's largest dermatology practice is opening a new clinic in Issaquah, bringing comprehensive skin care to a competitive, growing market.

For the 5th straight year, WA's life sciences outpace job growth. See how AI leadership and strategic investment fuel its $43.4B economic impact.

As Varex prepares its Q2 report, investors watch to see if booming industrial sales and medical innovations can sustain its impressive market momentum.

By achieving rigorous ONC certification, surgeon-developed 4D EMR is enhancing data security and interoperability for the unique needs of plastic surgery.

With rising cancer rates, Utepreva's innovative sampler promises more accurate and comfortable tissue collection, potentially transforming early diagnosis.

The arrival of South Africa's first generic hormonal IUD aims to tackle high costs and low uptake of long-acting contraception in a nation of high unplanned pregnancies.

Hundreds of lupus advocates descended on Washington, demanding policy reform and research funding, and their persistent efforts are already yielding major results.

EXALTA Group's new ISO 17025 accreditation for its in-house lab aims to slash development time, reflecting a broader industry push for integrated partners.

A $500K grant accelerates a novel therapy that dismantles tumor defenses, offering new hope for patients with hard-to-treat gastroesophageal cancers.

A new imaging tool eliminates background noise, offering a revolutionary, high-definition view into the cellular processes that drive life and disease.

With its fiscal 2026 results imminent, STERIS faces high expectations amid market pressures, offering a key indicator for the global healthcare sector.

The diabetes tech firm posted a 57% revenue jump and lifted its 2026 outlook, but a sequential drop in new users raises questions for investors.

New data shows Synthekine's STK-012 overcomes resistance to standard therapy, offering hope for patients with immune-cold non-small cell lung cancer.

Remix Therapeutics' first-in-class drug REM-422 targets a rare cancer at its genetic source, with pivotal data set for a major oncology conference.

VSI surgeons performed the world's first spine surgery with an AI-powered robotic system, promising a new era of surgical precision and patient safety.

Adocia extends its cash runway to 2027 with a new loan, but the deal could make its key investor the largest shareholder, creating a dilution dilemma.

A volunteer army and cutting-edge science converge this May to combat brain cancer, a disease with grim survival rates and a devastating toll on the young.

New long-term data for FLT201 gene therapy could signal a paradigm shift from lifelong treatments for patients with Gaucher disease type 1.